2020
DOI: 10.21608/bfsa.2020.34632.1013
|View full text |Cite
|
Sign up to set email alerts
|

Real-world safety and efficacy of ticagrelor in patients with ST segment elevation myocardial infarction at Assiut University Heart Hospital

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…However, rather than relying on any test in clinical practice, for reasons such as drug-related side effects (dyspnea, arrhythmia, etc. ), major and minor bleeding complications, newly started anticoagulant drugs, drug incompatibility or emerging clinical conditions such as previous stroke; de-escalation of potent antiaggregant to classical clopidogrel appears to be applied [ 8 ]. As a matter of fact, in our patient, de-escalation was applied to clopidogrel due to the major bleeding complication in hospitalization without any PFT or genetic testing.…”
Section: Discussionmentioning
confidence: 99%
“…However, rather than relying on any test in clinical practice, for reasons such as drug-related side effects (dyspnea, arrhythmia, etc. ), major and minor bleeding complications, newly started anticoagulant drugs, drug incompatibility or emerging clinical conditions such as previous stroke; de-escalation of potent antiaggregant to classical clopidogrel appears to be applied [ 8 ]. As a matter of fact, in our patient, de-escalation was applied to clopidogrel due to the major bleeding complication in hospitalization without any PFT or genetic testing.…”
Section: Discussionmentioning
confidence: 99%